Recommendation Of Oncotype DX In National Comprehensive Cancer Network Guidelines
Genomic Health's Oncotype DX breast cancer assay, used to predict the likelihood of disease recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients, has been included in the National Comprehensive Cancer Network (NCCN) 2008 Breast Cancer Treatment Guidelines.
Oncotype DX is the only multi-gene expression assay to be recommended by NCCN, an alliance of 21 world-leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer.
"We are pleased that NCCN, a leader in promoting quality cancer care, has included use of Oncotype DX for early-stage breast cancer patients," said Steven Shak, M.D., chief medical officer at Genomic Health. "With their recommendation, the recent inclusion of Oncotype DX in ASCO Guidelines and the majority of U.S. insured lives covered for Oncotype DX, it is clear the clinical community has accepted the test as standard practice for making individualized breast cancer treatment decisions."
Oncotype DX has been validated through multiple independent clinical studies involving more than 3,300 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. Inclusion in NCCN's updated treatment guidelines, released today, reinforces the significance of molecular diagnostics in breast cancer treatment planning and in particular the value of the individualized information provided by Oncotype DX.